Enter your search terms:

DiagNodus Ltd focuses on developing new approaches to detection, screening and monitoring of Inflammatory Bowel Disease (IBD) and Colorectal Cancer (CRC) affecting millions of people worldwide. Our patented innovative concept involving non-invasive sampling followed by diagnostic biomarker quantification has been successfully proven for IBD in a completed clinical study. We have designed a new diagnostic product for IBD detection and monitoring in point-of-care (POC) format and currently look for funding (2-3 M Euros) to support product development. Parallel work on CRC (an innovative approach to CRC screening) has been started (clinical study currently in progress).